

## Reimbursement & Policy

### Safety monitoring the additional dose of the Pfizer vaccine

Last week, a third dose of the Pfizer-BioNTech vaccine **was authorized** for those aged ≥ 65 years, at high risk for severe COVID-19, or whose occupational or institutional exposure puts them at high risk – including frontline healthcare workers. This is the second authorization of a third dose for the Pfizer vaccine. In August, the FDA and CDC recommended immunocompromised individuals also seek a third dose.


Initial data on adverse reactions were based on 306 persons in a Phase III clinical trial. Today, CDC published additional safety data submitted to their v-safe system, a voluntary, smartphone-based surveillance system.

Data collected from 12,591 v-safe participants during August 12–September 19, 2021 demonstrated similar safety profiles between the 3rd and 2nd booster doses of an mRNA COVID-19 vaccine (i.e. not all patients received 3 doses of the Pfizer-BioNTech COVID-19 Vaccine). Local and systemic reactions to the 3rd dose of the vaccine occurred in 79.4% and 74.1% of patients, respectively, compared to local and systemic reactions to the 2nd dose of the vaccine in 77.6% and 76.5% of patients, respectively.

Local or systemic adverse reactions were most commonly reported in the 7 days after the additional dose. The most commonly reported adverse reactions were injection site pain (15,761; 71.0%), fatigue (12,429; 56.0%), and headache (9,636; 43.4%). A small proportion of v-safe respondents reported seeking medical care post-vaccination: 1.8% sought medical care, and 0.1% were hospitalized. Reasons for receiving medical care or hospitalization are not collected in the v-safe survey.

More information on these data can be found [here](#).

KTVB in Boise spent time in two Idaho ICU units last week. The first video is from Minidoka Memorial in Rupert; the second, Saint Alphonsus in Boise.



## Virtual Meetings & Education

### Webinar: Fatigue following COVID

For providers, this COCA call will focus on fatigue in patients after having COVID. No pre-registration is needed, simply click the link to join the event.

**Evaluating and supporting patients presenting with fatigue following COVID**

September 30 ~ 12-1p MTN / 11a-12p PAC

[Join webinar](#)

[Click to get our COVID-19 Updates](#)

Share this email:



[Manage](#) your preferences | [Opt out](#) using TrueRemove™

Got this as a forward? [Sign up](#) to receive our future emails.

View this email [online](#).

615 N. 7th St.  
Boise, ID | 83701 US

This email was sent to .  
To continue receiving our emails, add us to your address book.

emma